US/UK/Canada

Share

Pick a time period -
Tags ( Active)

Extended acceptance period in Progenics' offer to acquire the shares in EXINI has ended

On 13 October 2015 Progenics Pharmaceuticals, Inc. ("Progenics") announced a cash offer to the shareholders of EXINI Diagnostics AB (publ) ("EXINI") to acquire all outstanding shares in EXINI for SEK 3.15 in cash per share (the "Offer"). At the end of the initial acceptance period, which expired on 5 November 2015 at 5.00 p.m. (CET), the Offer had been accepted by shareholders representing a total of 16,993,873 shares, corresponding to approx. 92.45 percent of the total shares in EXINI. Progenics thus decided to complete the Offer and declared the Offer unconditional and extended the

Progenics completes the offer to acquire shares in EXINI and extends the acceptance period

On 13 October 2015 Progenics Pharmaceuticals, Inc. ("Progenics") announced a cash offer to the shareholders of EXINI Diagnostics AB (publ) ("EXINI") to acquire all outstanding shares in EXINI for SEK 3.15 in cash per share (the "Offer"). As of the end of the initial acceptance period, which expired on 5 November 2015 at 5.00 p.m. (CET), the Offer had been accepted by shareholders representing a total of 16,993,873 shares, corresponding to approx. 92.45 percent of the total shares in EXINI. All conditions of the Offer have thus been fulfilled and Progenics declares the Offer unconditional.

Progenics announces a recommended cash offer to the shareholders of EXINI

Progenics Pharmaceuticals, Inc. ("Progenics"), a US company whose shares are quoted on The NASDAQ Stock Market LLC, New York, under the symbol PGNX, hereby announces a cash offer to the shareholders of EXINI Diagnostics AB (publ) ("EXINI") to acquire all outstanding shares in EXINI (the "Offer"). The EXINI shares are listed on Nasdaq First North, Stockholm. The EXINI Board has unanimously recommended that their shareholders accept the Offer. Summary of the Offer · Progenics offers SEK 3.15 in cash for each share in EXINI.[1]  The Offer values all outstanding shares in

There are no items matching the current filter
There are no more items matching the current filter
Back to top